CeraVe, AcneFree, Ambi acquired by L'Oréal
L'Oréal agreed to acquire CeraVe, AcneFree, Ambi, a skincare brand on Jan 10, 2017. FundComb records estimated consideration of USD 1.3bn. The current comp implies EV / revenue of 7.7x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- CeraVe, AcneFree, Ambi
- Acquirer
- L'Oréal
- Seller
- Valeant Pharmaceuticals
- Announced
- 2017-01-10
- Geography
- -
- Tags
- Acne CareCPGDermatology SkincareSkincare
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-15
- Latest update
- 2026-06-15
Parties at the deal date
Acquirer
L'Oréal BOLD (Business Opportunities for L'Oréal Development) is L'Oréal's corporate venture capital fund, investing in startups across the beauty value chain including beauty brands, platforms, technology, and science for beauty.
Snapshot preserved for this transaction; current company profiles may differ.
Value and multiples
Price / value
USD 1.3B
Transaction value | USD
Basis: FundComb estimate
EV / revenue
7.7x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 1.3bn transaction value is a FundComb estimate. Public sources reviewed confirm the transaction, but do not independently disclose every valuation input.
- Implied EV / revenue is 7.7x, calculated from USD 1.3bn value and USD 169m revenue.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Source summary
No public source summary has been published for this transaction yet.